drugset
Drugs / INZ-701
last change Feb 2026 re-read 2 minutes ago

INZ-701

also known as rhENPP1-Fc

Protein / enzyme biologic targets ENPP1 via restoration

Developed for
pseudoxanthoma elasticum (inherited or acquired) · calciphylaxis
Investigated by
Inozyme Pharma · BioMarin Pharmaceutical · IQVIA Biotech

Trials 8 · a red edge is where a trial was stopped

today NCT07473973 · Ph 3 NCT06739980 · Ph 2 NCT06462547 · Ph 2 NCT06283589 · Ph 1 NCT06046820 · Ph 3 NCT05734196 · Ph 1 NCT05030831 · Ph 1/2 NCT04686175 · Ph 1/2
2022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06283589 Feb → Jul 2024 calciphylaxis Inozyme Pharma Completed No outcome recorded
Phase 1 NCT05734196 Jun 2023 → Nov 2027 expected arterial calcification of infancy, autosomal recessive hypophosphatemic rickets, pseudoxanthoma elasticum (inherited or acquired) Inozyme Pharma Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05030831 Apr 2022 → Jul 2024 arterial calcification of infancy, pseudoxanthoma elasticum (inherited or acquired) Inozyme Pharma Completed No outcome recorded
Phase 1/2 NCT04686175 Nov 2021 → Oct 2024 arterial calcification of infancy, autosomal recessive hypophosphatemic rickets Inozyme Pharma Completed No outcome recorded
Phase 22 trials
Phase 2 NCT06739980 Jan 2025 → Mar 2027 arterial calcification, generalized, of infancy, 1, autosomal recessive hypophosphatemic rickets Inozyme Pharma Withdrawn No outcome recorded
Phase 2 NCT06462547 Jun 2024 → Nov 2030 expected calcinosis, hypophosphatemic rickets, autosomal recessive, 2, pseudoxanthoma elasticum (inherited or acquired) Inozyme Pharma Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07473973 Mar 2025 → Sep 2028 expected arterial calcification, generalized, of infancy, 1, autosomal recessive hypophosphatemic rickets Inozyme Pharma Recruiting No outcome recorded
Phase 3 NCT06046820 Nov 2023 → Jan 2026 overdue arterial calcification of infancy, autosomal recessive hypophosphatemic rickets Inozyme Pharma Active not recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as INZ-701 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739980 ↗
7

NCT05030831 ↗

NCT04686175 ↗

NCT06283589 ↗

NCT07473973 ↗

NCT05734196 ↗

NCT06046820 ↗

NCT06462547 ↗
Known as rhENPP1-Fc “INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).” NCT05030831 ↗
1

“INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).” NCT06462547 ↗
Action Restore “INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy in development for the treatment of the ultra-rare genetic disorder, ENPP1...” NCT05734196 ↗
Modality Protein / enzyme biologic “INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.” NCT04686175 ↗
Route Subcutaneous “by subcutaneous (SC) injection” NCT06046820 ↗
Target ENPP1 “contains the extracellular domains of human ENPP1” NCT04686175 ↗